Compass Therapeutics, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Compass Therapeutics Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000634). The filing signals that the institutional investor has crossed the key 5% beneficial ownership threshold in the clinical-stage biopharmaceutical company. Such 13G disclosures are typically passive in nature and do not imply activist intent. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments that clarify the size and nature of State Street's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Compass Therapeutics, Inc., State Street Corp